|
C19-9
- 英文名称：C19-9
- 品牌：WYTSCI
- 产地：进口
- 型号：1MG
- 货号：WT-AY-B11041
- cas：1477482-47-5
- 价格： ￥1/mg
- 发布日期： 2025-04-10
- 更新日期： 2025-12-08
产品详请
| 产地 | 进口 |
| 品牌 | WYTSCI |
| 货号 | WT-AY-B11041 |
| 用途 | 科研检测 |
| 英文名称 | C19-9 |
| 包装规格 | 1MG |
| CAS编号 | 1477482-47-5 |
| 别名 | C19-9 |
| 纯度 | 98+% |
| 分子式 | |
| 是否进口 | 是 |
纯度:>98% by TLC;NMR (Conforms)
分子式:C16H18N4O3
分子量:314.35
溶剂:DMSO (>50 mg/ml)
性状:White to off-white solid
存储:-20°C
Activity (short version):non-RGD integrin αv?3 receptor inhibitor
Function / Pharmacology:C19-9 (1477482-47-5) is a novel non-RGD inhibitor of the integrin αv?3 receptor (KD = 102 nM). It was active against the human prostate carcinoma epithelial cell line 22RV1 (IC50 = 467 nM) and human prostate cancer organoids (IC50 = 652 nM). C19-9 was active in vivo in 22RV1 mouse xenografts and blocked growth in enzalutamide-resistant mouse CRPC xenografts.
分子式:C16H18N4O3
分子量:314.35
溶剂:DMSO (>50 mg/ml)
性状:White to off-white solid
存储:-20°C
Activity (short version):non-RGD integrin αv?3 receptor inhibitor
Function / Pharmacology:C19-9 (1477482-47-5) is a novel non-RGD inhibitor of the integrin αv?3 receptor (KD = 102 nM). It was active against the human prostate carcinoma epithelial cell line 22RV1 (IC50 = 467 nM) and human prostate cancer organoids (IC50 = 652 nM). C19-9 was active in vivo in 22RV1 mouse xenografts and blocked growth in enzalutamide-resistant mouse CRPC xenografts.
